Short Interest in Harvard Bioscience, Inc. (NASDAQ:HBIO) Declines By 24.1%

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totaling 445,314 shares, a drop of 24.1% from the December 15th total of 586,355 shares. Based on an average trading volume of 565,892 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.1% of the company’s stock are short sold. Currently, 1.1% of the company’s stock are short sold. Based on an average trading volume of 565,892 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Investors Weigh In On Harvard Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC boosted its stake in shares of Harvard Bioscience by 491.9% during the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 58,785 shares during the last quarter. Williams & Novak LLC lifted its stake in shares of Harvard Bioscience by 37.0% during the second quarter. Williams & Novak LLC now owns 106,570 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 28,800 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Harvard Bioscience by 278.3% during the third quarter. Assenagon Asset Management S.A. now owns 139,220 shares of the medical instruments supplier’s stock valued at $61,000 after buying an additional 102,419 shares during the period. Marshall Wace LLP acquired a new stake in Harvard Bioscience during the second quarter worth approximately $61,000. Finally, Bank of America Corp DE grew its stake in Harvard Bioscience by 44.4% in the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after acquiring an additional 11,948 shares during the period. 80.87% of the stock is currently owned by institutional investors and hedge funds.

Harvard Bioscience Stock Performance

Shares of NASDAQ:HBIO traded up $0.01 on Friday, reaching $0.59. 263,102 shares of the company were exchanged, compared to its average volume of 328,839. The company has a 50-day moving average of $0.68 and a 200-day moving average of $0.55. Harvard Bioscience has a 1-year low of $0.28 and a 1-year high of $1.98.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HBIO shares. Zacks Research raised Harvard Bioscience to a “hold” rating in a report on Thursday, December 11th. Wall Street Zen upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a research note on Monday, November 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.00.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.